Ulster University Logo

Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon

Ward, Joseph B.J., Lajczak, Natalia K., Kelly, Orlaith B, O'Dwyer, Aoife M., Giddam, Ashwini K, Ní Gabhainn, Joan N, Franco, Placido, Tambuwala, Murtaza M, Jefferies, Caroline A, Keely, Simon, Roda, Aldo and Keely, Stephen Joseph (2017) Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon. American Journal of Physiology - Gastrointestinal and Liver Physiology, n/a . [Journal article]

[img] Text - Accepted Version
679kB
[img] Text - Supplemental Material
Restricted to Repository staff only

62kB

URL: http://dx.doi.org/10.1152/ajpgi.00256.2016

DOI: 10.1152/ajpgi.00256.2016

Abstract

Inflammatory bowel diseases (IBD) are a group of common and debilitating chronic intestinal disorders for which currently-available therapies are often unsatisfactory. The naturally-occurring secondary bile acid, ursodeoxycholic acid (UDCA), has well-established anti-inflammatory and cytoprotective actions and may therefore be effective in treating IBD. Here, we aimed to investigate regulation of colonic inflammatory responses by UDCA and to determine the potential impact of bacterial metabolism on its therapeutic actions. The anti-inflammatory efficacy of UDCA, a non-metabolisable analogue, 6-methyl-UDCA (6-MUDCA), and its primary colonic metabolite, lithocholic acid (LCA), were assessed in the murine DSS model of mucosal injury. The effects of bile acids on cytokine release (TNF-α, IL-6, Il-1β, IFN-γ) from cultured colonic epithelial cells and mouse colonic tissue in vivo were investigated. Luminal bile acids were measured by GC-MS. UDCA attenuated release of proinflammatory cytokines from colonic epithelial cells in vitro and was protective against the development of colonic inflammation in vivo. In contrast, although 6-MUDCA mimicked the effects of UDCA on epithelial cytokine release in vitro, it was ineffective in preventing inflammation in the DSS model. In UDCA-treated mice, LCA became the most common colonic bile acid. Finally, LCA treatment more potently inhibited epithelial cytokine release and protected against DSS-induced mucosal inflammation than did UDCA. These studies identify a new role for the primary metabolite of UDCA, LCA, in preventing colonic inflammation and suggest that microbial metabolism of UDCA is necessary for the full expression of its protective actions.

Item Type:Journal article
Keywords:inflammatory bowel disease, bile acid, Epithelium, Cytokine, barrier function
Faculties and Schools:Faculty of Life and Health Sciences > School of Pharmacy and Pharmaceutical Science
Faculty of Life and Health Sciences
Research Institutes and Groups:Biomedical Sciences Research Institute
Biomedical Sciences Research Institute > Pharmacy & Pharmaceutical Sciences
ID Code:37488
Deposited By: Mrs Caroline Adams
Deposited On:13 Apr 2017 15:04
Last Modified:31 Mar 2018 22:23

Repository Staff Only: item control page